Antibody/Targeted-Drug Conjugates 2017

22-24 March 2017, Leiden University Medical Centre, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size


Join the conversation on Twitter – #ATDC2017

The concept of using biologics and particles including monoclonal antibodies to deliver drugs to disease targets such as cancer cells has been explored for decades, with early work surrounding non-specific targets and drugs with low potencies. These studies highlighted the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics and conjugation methodology, in developing effective targeted drug conjugates with acceptable safety/toxicity profiles.

The second ATDC New Developments & Updates conference to be held in Leiden, The Netherlands in March 2017 will aim to examine the concept and future of targeted drug delivery systems to include antibodies/bispecific antibodies/proteins/nanoparticles and other biologics.

The ATDC 2017 scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects and recent developments surrounding targeted drug delivery systems.

Abstracts for oral and poster presentation are called for – please see the participation page for abstract submission details.

Scientific Advisory Panel

John A. Flygare (Merck Inc., USA)
Greg Bleck (Catalent Pharma Solutions, Somerset, New Jersey, USA)
Victor Goldmacher (Cancer Targeting Solutions LLC, USA)
John Lambert (ImmunoGen Inc., Waltham, Massachusetts, USA)
Roger R. Beerli (NBE-Therapeutics LLC, Basel, Switzerland)
Michael Firer (Ariel University, Ariel, Israel)
Alain Beck (Centre d’Immunologie Pierre Fabre, St Julien-en-Genevois, France)
Philip Howard (MedImmune/Spirogen Ltd, London, UK)
Peter Hofland (InPress Media Group, Phoenix, Arizona, USA)
David Rabuka (Catalent Pharma Solutions, Somerset, New Jersey, USA)
Peter Park (Bicycle Therapeutics Inc., Cambridge, Massachusetts, USA)
Hendrik Jan Houthoff (LinXis Pharmaceuticals BV, Amsterdam, The Netherlands)
Deyarina Gonzalez (Swansea University Medical School, Swansea, Wales, UK)
Chris Scott (Queen’s University Belfast, Belfast, UK)
Ulrich Storz (Michalski Hattermann & Partners , Dusseldorf, Germany)
Aad van de Leur (Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands)
Floris van Delft (Synaffix BV, Oss, The Netherlands)

Conference Scope and Topics

  • Novel ADC targets/ADC target discovery/target disease indications (including  non-cancer targets)
  • Novel payloads/modes of action (beyond tubulin binders)
  • Biological components (antibody & antibody-like formats; molecularly defined conjugation sites)
  • Chemical components: Linker/payload combinations; optimization of linker chemistry; cleavable linkers
  • Next generation ADCs (site-specifically conjugated, including enzymatic conjugation
  • Immunotoxins
  • Chemistry approaches: mediating high toxicity of new warheads currently in use
  • Chemical modifications of ADC structure and linkers
    Improving the therapeutic index – toxicity reduction efforts avoiding efficacy reduction
  • Other carrier/delivery possibilities beyond antibodies and bispecific antibodies (nanoparticles, peptides, aptamers, hormones and their analogues, small molecules, liposomes, vitamins)
  • Manufacturing/Regulatory issues
  • Process development (robustness, scalability)
  • Clinical stage ADCs/ongoing clinical trials, clinical translation

ATDC 2017 Delegates

Login details will be supplied after you have registered for the event.

ATDC 2017 Sponsors

  • ImmunoGen
  • Catalent
  • Genovis
  • ONdrugDelivery
  • Pfizer Oncology
  • NBE Therapeutics
  • Cancer Targeting Solutions Consultancy
  • Lonza
  • ADC Review
  • Oncozine
  • LinXis
  • Aldevron
  • Sutro BioPharma
  • Genentech

ATDC 2017 Downloads

ATDC 2017 Leaflet

ATDC 2017 Mailing List

E-mail Address
What is 3+2-1?